Literature DB >> 8217542

Desferrioxamine and urinary zinc excretion in beta-thalassemia major.

Z Uysal1, N Akar, S Kemahli, N Dincer, A Arcasoy.   

Abstract

This study has been undertaken to find out whether urinary zinc excretion, which is already increased in patients with thalassemia, is further increased by usual and high doses of desferrioxamine (DF). A total of 11 beta-thalassemia major patients were included. DF infusions have been performed with doses, either 50 mg/kg or 150 mg/kg. Nine age and sex matched normal children were taken as the control group. The mean basal-Zn excretion of the patients was significantly higher than the mean Zn excretion observed in controls. No significant difference is observed between the mean Zn excretion obtained on different doses of DF. However, they are both significantly higher than the mean basal-Zn levels of the controls.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217542     DOI: 10.3109/08880019309029493

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations.

Authors:  Elijah K Goldberg; Ashutosh Lal; Ellen B Fung
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.289

2.  Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial.

Authors:  Ellen B Fung; Janet L Kwiatkowski; James N Huang; Ginny Gildengorin; Janet C King; Elliott P Vichinsky
Journal:  Am J Clin Nutr       Date:  2013-08-14       Impact factor: 7.045

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.